Dexrazoxane for the treatment of chemotherapy-related side effects

2014/09/01 by Seppo W. Langer · 3 citations
Medicine · #Chemotherapy-related skin toxicity #Cancer Treatment and Pharmacology #Chemotherapy-induced cardiotoxicity and mitigation

paper · pdf · doi:10.2147/cmar.s47238

openalex publication_date 2014/09/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.

Citations

• Targeting DNA topoisomerase II in cancer chemotherapy

Cited by

• Topoisomerases as anticancer targets
• DNA topoisomerases as molecular targets for anticancer drugs
• Topoisomerase inhibitor [wikipedia]

Related

• Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study
• Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients
• Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group
• Anthracycline Chemotherapy and Cardiotoxicity
• DUAL USE RESEARCH OF CONCERN: DERIVATIVES OF 3-QUINUCLIDINYL BENZILATE (BZ)